Navigation Links
MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
Date:1/31/2008

applicable securities laws in Canada, (collectively referred to as "forward-looking statements"). Statements, other than statements of historical fact, are forward-looking statements and include, without limitation, statements regarding our strategy, future operations, timing and completion of clinical trials, prospects, plans and objectives of management. The words "anticipates", "believes", "budgets", "could", "estimates", "expects", "forecasts", "intends", "may", "might", "plans", "projects", "schedule", "should", "will", "would" and similar expressions are often intended to identify forward-looking statements, which include underlying assumptions, although not all forward-looking statements contain these identifying words. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other things contemplated by the forward-looking statements will not occur.

Although our management believes that the expectations represented by such forward-looking statements are reasonable, there is significant risk that the forward-looking statements may not be achieved, and the underlying assumptions thereto will not prove to be accurate. Forward-looking statements in this news release include, but are not limited to, statements concerning our expectations for: increasing the celgosivir dose to 600mg being an important development step for the optimization and advancement of celgosivir; our plans to add approximately six patients at 600mg dose in the celgosivir Phase II viral kinetics study and having results from the study in the third quarter 2008; Cadence Pharmaceuticals completing enrollment in the CLIRS trial in the second quarter of 2008, with results available in the second half of 2008; and Cutanea Life Sciences' plans to advance omiganan for the treatment of rosacea to Phase III clinical developme
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results
2. MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
3. MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
5. MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
6. MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
7. Dey L.P. and Critical Therapeutics Launch Twice-Daily ZYFLO CR(TM) (Zileuton) Extended-Release Tablets for the Chronic Treatment of Asthma
8. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
9. Oncolytics Biotech Inc. Proceeds to Full Enrolment in U.S. Phase II Sarcoma Clinical Trial
10. Phase 1 Studies Show Promise of QuatRxs Novel Compound, Sobetirome, for Lowering LDL Cholesterol Levels
11. Surface Logix Achieves Objectives With SLx-4090 in Phase 2a Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... -- Research and Markets has announced the ... & Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, Sequencing) Market ... The global molecular biology enzymes market ... expected to grow at a CAGR of 13.74% to ... & reagents find applications in a large number of ...
(Date:8/22/2014)... Angeles (PRWEB) August 22, 2014 ... age-defying products, is in the spotlight again. Nerium ... cream and its NeriumFirmTM Body Contouring Cream to ... by Backstage Creations during the 66th Primetime Emmy® ... patented NAE-8® extract, third-party clinical trials show that ...
(Date:8/22/2014)... “Our nation's healthcare system is broken, ... Furthermore, every governmental and professional entity that has ... of unorganized dysfunction shares in that enormous blame. ... as a device to use in an effort ... have accumulated through the years leading to the ...
(Date:8/21/2014)... PA & Rockville, MD (PRWEB) August 21, 2014 ... (ITI) is making progress in its development of ... to Japanese red cedar pollen. Phase IC studies began ... a real solution to hay fever. , The Japanese ... over 35 million people in Japan. Mountain Cedar pollen ...
Breaking Biology Technology:Global Molecular Biology Enzymes, Kits, & Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, Sequencing) Market - Forecast to 2018 2Global Molecular Biology Enzymes, Kits, & Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, Sequencing) Market - Forecast to 2018 3Nerium International Joins Television’s Biggest Stars at Backstage Creations Giving Suite at the 66th Primetime Emmy Awards 2Nerium International Joins Television’s Biggest Stars at Backstage Creations Giving Suite at the 66th Primetime Emmy Awards 35 Great Mistakes in Healthcare and How to Fix Them by Dr. Ira Williams 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 3Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 4
... Combination of Panzem(R) NCD and Avastin(R) May ... 28 EntreMed, Inc.,(Nasdaq: ENMD ), ... treatment of cancer and inflammatory diseases, today,announced ... Phase 2 multi-center,study combining Panzem(R) NCD with ...
... PARIS, January 28 Sanofi-aventis announced,today that ... approved for marketing in Japan by the ... prevention of venous thromboembolism (VTE) in patients,undergoing ... as total hip,replacement, total knee replacement and ...
... Inc.,(NYSE: FRX ), Forest Laboratories Holdings, Ltd., ... GmbH announced that they have filed a second,lawsuit ... of Delaware against,additional companies for infringement of U.S. ... Forest,s Namenda(R) product. The defendants,named in the lawsuit ...
Cached Biology Technology:EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study 2EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study 3EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study 4Clexane(R)/Lovenox(R) Approved in Japan 2Clexane(R)/Lovenox(R) Approved in Japan 3Clexane(R)/Lovenox(R) Approved in Japan 4Clexane(R)/Lovenox(R) Approved in Japan 5Forest Laboratories, Inc. and Merz Pharma GmbH & Co. KgaA File Additional Lawsuit Against Several Companies for Patent Infringement 2
(Date:8/22/2014)... tea polyphenols are strong antioxidants and can ... spinal cord neurons against oxidative stress? Jianbo ... Hospital of Liaoning Medical University, China discovered ... stress and inhibit neuronal apoptosis, indicating green ... spinal cord neurons under oxidative stress. The ...
(Date:8/22/2014)... American consumers will finally be able to purchase fuel ... as zero-emissions vehicles, most of the cars will run ... that contributes to global warming. , Now scientists at ... uses an ordinary AAA battery to produce hydrogen by ... through two electrodes that split liquid water into hydrogen ...
(Date:8/21/2014)... Ga. An international team of scientists including researchers from ... Brassica napus commonly known as canolain the journal Science ... the plant, which is used widely in farming and industry. ... its native Europe, but the winter crop is increasingly cultivated ... its naturally low levels of saturated fat and rich supply ...
Breaking Biology News(10 mins):Stanford scientists develop a water splitter that runs on an ordinary AAA battery 2Stanford scientists develop a water splitter that runs on an ordinary AAA battery 3Canola genome sequence reveals evolutionary 'love triangle' 2
... HUNTSVILLE, TX (Feb. 21, 2012)-- An assistant ... Criminal Justice is working to unlock the mysteries ... play on criminal and antisocial behavior. "Biosocial ... behavior," said Dr. Brian Boutwell. "It involves aspects ...
... 2012A team of researchers has found a way to ... to be available, despite the potential attack of Xylella ... poses a significant threat to the California wine industry,s ... Laboratory (LANL), University of California at Davis (UCD), and ...
... prospective study of ethnic differences in the symptoms of ... background have more delayed language, communication and gross motor ... the Kennedy Krieger Institute concluded that subtle developmental delays ... severe symptoms develop. While the prevalence of autism ...
Cached Biology News:Are there biosocial origins for antisocial behavior? 2More grapes, less wrath: Hybrid antimicrobial protein protects grapevines from pathogen 2New study shows minority toddlers with autism are more delayed than affected Caucasian peers 2New study shows minority toddlers with autism are more delayed than affected Caucasian peers 3
... Tissue Array (MSTA) slides were designed to study ... from multiple species. Tissue slices from three ... which can then be treated as a single ... in situ hybridization. This format allows ...
... Clear yellow solution. In ... thimerosal, and other proprietary ... Diluent formulated to stabilize ... antibody conjugates at high ...
... used to predict the melting ... up to 3,200 bases, which ... primers and GC clamps for ... gel electrophoresis (DGGE), constant denaturing ...
... Mini-Sub cell GT cell and PowerPac basic power ... of nucleic acids in agarose gels. The Mini-Sub ... with cables and electrodes, a 7 x 7 ... casting gates, and two 1.5 mm fixed-height combs ...
Biology Products: